Biotechs Target Cancer Metabolism
This article was originally published in Start Up
As reseachers uncover linkages between tumor formation and cellular metabolism, start-ups and their venture backers see an opportunity to create a new class of cancer medicines. In this issue, we profile Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals.
You may also be interested in...
With late-stage assets scarce, Campbell Alliance consultants offer tips for spotting early oncology opportunities, as part of Windhover’s Therapeutic Area Partnerships annual showcase of top unpartnered assets. MEI Pharma, Macrogenics and EnGeneIC are among the companies featured this year.
Forma has garnered a deal with J&J subsidiary Janssen Pharmaceuticals to develop and commercialize treatments for tumor metabolism.
Cancer metabolism specialist Agios extends research collaboration with Celgene, picking up an additional $20 million.